Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Tonix showcases Phase 3 data for FDA-approved Tonmya at PAINWEEK 2025, eyes launch next quarter
MP3•Episode home
Manage episode 505928486 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share that the company presented four scientific posters at the PAINWEEK 2025 conference in Las Vegas, Nevada, showcasing robust data from two pivotal Phase 3 trials of Tonmya® for the treatment of fibromyalgia. The first study, RELIEF, was a 14-week randomized, double-blind, placebo-controlled trial, while the second, RESILIENT, served as a confirmatory efficacy and safety trial. Results across both studies demonstrated that Tonmya significantly reduced fibromyalgia-related pain while maintaining a favorable tolerability profile. Unlike conventional pain therapies, Tonmya is designed to pharmacologically target nonrestorative sleep by antagonizing receptors that regulate sleep architecture—addressing a central mechanism thought to perpetuate fibromyalgia symptoms. Dr. Lederman noted that beyond reducing pain, Tonmya’s mechanism of action may help improve a wide spectrum of fibromyalgia symptoms, potentially supporting earlier diagnosis, timely intervention, and improved long-term outcomes. Importantly, the therapy represents a non-opioid treatment option at a time when safer alternatives are in high demand. With FDA approval secured, Tonix is now preparing to launch Tonmya commercially in the coming quarter, marking a transformative milestone for both the company and the fibromyalgia community. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #Tonmya #Fibromyalgia #FDAApproval #NonOpioid #PainManagement #ChronicPain #NociplasticPain #Cyclobenzaprine #MoveFibroForward #Painweek2025
…
continue reading
606 episodes
MP3•Episode home
Manage episode 505928486 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share that the company presented four scientific posters at the PAINWEEK 2025 conference in Las Vegas, Nevada, showcasing robust data from two pivotal Phase 3 trials of Tonmya® for the treatment of fibromyalgia. The first study, RELIEF, was a 14-week randomized, double-blind, placebo-controlled trial, while the second, RESILIENT, served as a confirmatory efficacy and safety trial. Results across both studies demonstrated that Tonmya significantly reduced fibromyalgia-related pain while maintaining a favorable tolerability profile. Unlike conventional pain therapies, Tonmya is designed to pharmacologically target nonrestorative sleep by antagonizing receptors that regulate sleep architecture—addressing a central mechanism thought to perpetuate fibromyalgia symptoms. Dr. Lederman noted that beyond reducing pain, Tonmya’s mechanism of action may help improve a wide spectrum of fibromyalgia symptoms, potentially supporting earlier diagnosis, timely intervention, and improved long-term outcomes. Importantly, the therapy represents a non-opioid treatment option at a time when safer alternatives are in high demand. With FDA approval secured, Tonix is now preparing to launch Tonmya commercially in the coming quarter, marking a transformative milestone for both the company and the fibromyalgia community. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #Tonmya #Fibromyalgia #FDAApproval #NonOpioid #PainManagement #ChronicPain #NociplasticPain #Cyclobenzaprine #MoveFibroForward #Painweek2025
…
continue reading
606 episodes
Alle episoder
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.